Last reviewed · How we verify
grazoprevir/elbasvir, ribavirin
Grazoprevir/elbasvir is a combination of two antiviral drugs that inhibit the HCV NS3/4A protease and NS5A protein, respectively, to treat hepatitis C virus infection.
Grazoprevir/elbasvir is a combination of two antiviral drugs that inhibit the HCV NS3/4A protease and NS5A protein, respectively, to treat hepatitis C virus infection. Used for Chronic hepatitis C virus (HCV) infection in adults with compensated liver disease, including cirrhosis.
At a glance
| Generic name | grazoprevir/elbasvir, ribavirin |
|---|---|
| Also known as | Zepatier, Rebetol |
| Sponsor | University of Zurich |
| Drug class | NS3/4A protease inhibitor and NS5A inhibitor |
| Target | HCV NS3/4A protease and NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Grazoprevir is a NS3/4A protease inhibitor that blocks the proteolytic activity of the NS3/4A enzyme, preventing viral replication. Elbasvir is a NS5A inhibitor that binds to the NS5A protein, disrupting its function and preventing viral replication.
Approved indications
- Chronic hepatitis C virus (HCV) infection in adults with compensated liver disease, including cirrhosis
Common side effects
- Fatigue
- Headache
- Nausea
Key clinical trials
- Pembrolizumab (MK-3475) in Hepatocellular Carcinoma (PHASE2)
- Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients. (PHASE3)
- Zepatier in Patients with Substance Use
- Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients (PHASE1, PHASE2)
- ATTIC - Access To Treat in the Community (PHASE4)
- Transplanting Hepatitis C Lungs Into Negative Lung Recipients (PHASE1, PHASE2)
- Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel
- Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- grazoprevir/elbasvir, ribavirin CI brief — competitive landscape report
- grazoprevir/elbasvir, ribavirin updates RSS · CI watch RSS
- University of Zurich portfolio CI